 <h1>Percolone Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>oxycodone</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about oxycodone. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Percolone.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to oxycodone: oral capsule, oral capsule extended release, oral solution, oral tablet, oral tablet extended release</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Capsule, Extended Release)</p><p>Addiction, Abuse, and MisuseOxycodone extended-release (ER) exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing oxycodone ER, and monitor all patients regularly for the development of these behaviors or conditions.Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse and misuse, the Food and Drug Administration (FDA) has required a REMS for these products. Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers. Healthcare providers are strongly encouraged to: complete a REMS-compliant education program, counsel patients and/or their caregivers, with every prescription, on safe use, serious risks, storage, and disposal of these products, emphasize to patients and their caregivers the importance of reading the Medication Guide every time it is provided by their pharmacists, and consider other tools to improve patient, household, and community safety.Life-Threatening Respiratory DepressionSerious, life-threatening, or fatal respiratory depression may occur with use of oxycodone ER. Monitor for respiratory depression, especially during initiation of oxycodone ER or following a dose increase.Accidental IngestionAccidental ingestion of even one dose of oxycodone ER, especially by children, can result in a fatal overdose of oxycodone ER.Neonatal Opioid Withdrawal SyndromeProlonged use of oxycodone ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.Cytochrome P450 3A4 InteractionThe concomitant use of oxycodone ER with all cytochrome P450 3A4 inhibitors may result in an increase in oxycodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma concentration. Monitor patients receiving oxycodone ER and any CYP3A4 inhibitor or inducer.Risks from Concomitant Use with Benzodiazepines or Other CNS DepressantsReserve concomitant prescribing of oxycodone ER and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</p><p class="blackboxWarning-title">Oral route (Tablet; Tablet, Extended Release)</p><p>Addiction, abuse, and misuse, leading to overdose and death has been reported. Before prescribing, assess the patient's risk and watch for signs of the development of these behaviors. To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for these products. Serious and fatal respiratory depression may occur. Monitor for respiratory depression, especially when beginning treatment or increasing dose. Advise patients to swallow tablets whole to avoid overdose. Accidental ingestion can result in a fatal overdose, especially in children. Prolonged use in pregnancy may lead to life-threatening neonatal withdrawal syndrome. If oxycodone hydrochloride must be used during pregnancy, advise the patient of the risk and ensure that treatment will be available to the infant. Initiation of CYP3A4 inhibitors or discontinuation of CYP3A4 inducers can cause a fatal oxycodone hydrochloride overdose. Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients with inadequate alternative treatment options. Limit dosages and durations to the minimum required and follow patients for signs and symptoms of respiratory depression and sedation.</p><p class="blackboxWarning-title">Oral route (Solution)</p><p>Use caution when prescribing and administering oxycodone oral solution as dosing errors due to mg and mL could result in accidental overdose and death. Ensure the proper dose is indicated and dispensed. Oxycodone oral solution should be kept out of the reach of children. Seek emergency help immediately if accidental ingestion occurs.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, oxycodone (the active ingredient contained in Percolone) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking oxycodone:</p><p>
<i>Less common</i>
</p><ul>
<li>Chills</li>
<li>cold sweats</li>
<li>confusion</li>
<li>difficult or labored breathing</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>fever</li>
<li>tightness in the chest</li>
<li>twitching</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>blood in the urine</li>
<li>burning while urinating burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>chest pain</li>
<li>cough</li>
<li>decrease in the frequency of urination</li>
<li>decreased urine output</li>
<li>difficult or painful urination</li>
<li>difficulty in passing urine (dribbling)</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>dry mouth</li>
<li>fainting</li>
<li>fast, irregular, pounding, or racing heartbeat or pulse</li>
<li>feeling of warmth or heat</li>
<li>flushing or redness of the skin, especially on the face and neck</li>
<li>frequent urination</li>
<li>headache</li>
<li>hives, itching, or skin rash</li>
<li>increase in heart rate</li>
<li>increased thirst</li>
<li>increased volume of pale, dilute urine</li>
<li>lightheadedness</li>
<li>muscle pain or cramps</li>
<li>nausea</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>rapid breathing</li>
<li>rapid weight gain</li>
<li>seizures</li>
<li>severe constipation</li>
<li>severe vomiting</li>
<li>stomach pain</li>
<li>sunken eyes</li>
<li>sweating</li>
<li>swollen, painful, or tender lymph glands in the neck, armpit, or groin</li>
<li>thirst</li>
<li>trembling or shaking of the hands or feet</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
<li>vomiting</li>
<li>wrinkled skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blurred vision</li>
<li>choking</li>
<li>clay-colored stools</li>
<li>cold, clammy skin</li>
<li>dark urine</li>
<li>diarrhea</li>
<li>fast, weak pulse</li>
<li>gagging</li>
<li>irregular, fast, slow, or shallow breathing</li>
<li>loss of appetite</li>
<li>loss of consciousness</li>
<li>pale or blue lips, fingernails, or skin</li>
<li>unpleasant breath odor</li>
<li>very slow heartbeat</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking oxycodone:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Change in consciousness</li>
<li>chest pain or discomfort</li>
<li>constricted, pinpoint, or small pupils (black part of the eye)</li>
<li>decreased awareness or responsiveness</li>
<li>extreme drowsiness</li>
<li>loss of consciousness</li>
<li>no muscle tone or movement</li>
<li>severe sleepiness</li>
<li>slow or irregular heartbeat</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of oxycodone may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Difficulty having a bowel movement</li>
<li>drowsiness</li>
<li>lack or loss of strength</li>
<li>relaxed and calm feeling</li>
<li>sleepiness or unusual drowsiness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Abnormal dreams</li>
<li>anxiety</li>
<li>belching</li>
<li>burning feeling in the chest or stomach</li>
<li>false or unusual sense of well-being</li>
<li>heartburn</li>
<li>hiccups</li>
<li>indigestion</li>
<li>stomach discomfort or upset</li>
<li>tenderness in the stomach area</li>
<li>trouble sleeping</li>
<li>weight loss</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Absent, missed, or irregular menstrual periods</li>
<li>bad, unusual or unpleasant (after) taste</li>
<li>bloated or full feeling</li>
<li>body aches or pain</li>
<li>change in taste</li>
<li>change in walking and balance</li>
<li>changes in vision</li>
<li>clumsiness or unsteadiness</li>
<li>congestion</li>
<li>continuous ringing or buzzing or other unexplained noise in the ears</li>
<li>crying</li>
<li>decreased interest in sexual intercourse</li>
<li>deep or fast breathing with dizziness</li>
<li>delusions of persecution, mistrust, suspiciousness, or combativeness</li>
<li>dental caries or tooth decay</li>
<li>depression</li>
<li>difficulty with speaking</li>
<li>dry skin</li>
<li>dryness or soreness of the throat</li>
<li>excess air or gas in the stomach or bowels</li>
<li>excessive muscle tone</li>
<li>feeling of constant movement of self or surroundings</li>
<li>feeling of unreality</li>
<li>general feeling of discomfort or illness</li>
<li>headache, severe and throbbing</li>
<li>hearing loss</li>
<li>hoarseness</li>
<li>inability to have or keep an erection</li>
<li>increase in body movements</li>
<li>increased appetite</li>
<li>increased cough</li>
<li>irritability</li>
<li>loss in sexual ability, desire, drive, or performance</li>
<li>loss of heat from the body</li>
<li>loss of memory</li>
<li>loss of strength or energy</li>
<li>muscle pain or weakness</li>
<li>muscle stiffness, tension, or tightness</li>
<li>neck pain</li>
<li>numbness of the feet, hands, and around the mouth</li>
<li>passing of gas</li>
<li>problems with memory</li>
<li>quick to react or overreact emotionally</li>
<li>rapidly changing moods</li>
<li>red, swollen skin</li>
<li>restlessness</li>
<li>runny nose</li>
<li>scaly skin</li>
<li>sensation of spinning</li>
<li>sense of detachment from self or body</li>
<li>severe sleepiness</li>
<li>swelling or inflammation of the mouth</li>
<li>voice changes</li>
</ul><p>
<!-- end oral capsule, oral capsule extended release, oral solution, oral tablet, oral tablet extended release --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to oxycodone: compounding powder, oral capsule, oral capsule extended release, oral concentrate, oral solution, oral tablet, oral tablet extended release</i></p><h3>General</h3><p>The most commonly reported adverse reactions in adults included constipation, nausea, somnolence, dizziness, vomiting, pruritus, headache, dry mouth, asthenia, and sweating.  In pediatric patients, the most frequently observed adverse reactions included vomiting, nausea, headache, pyrexia, and constipation.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (14%, pediatrics)</p>
<p><b>Common</b> (1% to 10%): Dizziness (pediatrics)</p>
<p><b>Frequency not reported</b>: Confusion, hypertonia, hypesthesia, nervousness, neuralgia, personality disorder, tremor, migraine</p>
<p><b>Postmarketing reports</b>: Serotonin syndrome<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Frequency not reported</b>: Apnea, respiratory arrest, bronchitis, cough increased, dyspnea, epistaxis, laryngismus, lung disorder, pharyngitis, rhinitis, sinusitis<sup>[Ref]</sup></p><p>Severe adverse effects such as respiratory depression can be treated with the opioid antagonist naloxone.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (23% to 27%), constipation (23% to 26%), vomiting (12% to 14%)</p>
<p><b>Frequency not reported</b>: Abdominal pain, anorexia, diarrhea, dyspepsia, dysphagia, gingivitis, glossitis<sup>[Ref]</sup></p><p>In pediatric studies with the oral extended release product, gastrointestinal adverse events were reported in 40% of patients 11 to 16 years of age (56 of 140); vomiting, nausea, constipation, and diarrhea were experienced by 21%, 15%, 9%, and 6%, respectively.  Abdominal pain and gastroesophageal reflux disease were reported in 1% to less than 5% of patients.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Paranoia, psychosis, hallucinations, agitation, anxiety<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Pruritus, hyperhidrosis, rash</p>
<p><b>Frequency not reported</b>: Herpes simplex, rash, sweating, urticaria<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Increased hepatic enzymes</p><h3>Cardiovascular</h3><p><b>Frequency not reported</b>: QTc prolongation at higher doses, deep thrombophlebitis, heart failure, hemorrhage, hypotension, palpitation, tachycardia, edema, peripheral edema, vasodilation, circulatory collapse<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Dysuria, urinary retention</p>
<p><b>Frequency not reported</b>: Urinary tract infection<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Allergic reaction</p>
<p><b>Postmarketing reports</b>: Anaphylaxis<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Flu syndrome, infection, sepsis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Decreased appetite (pediatrics)</p>
<p><b>Frequency not reported</b>: Gout, hyperglycemia, iron deficiency anemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Back pain, neck pain, arthralgia, arthritis, bone pain, myalgia, pathological fracture<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Photosensitivity reaction, amblyopia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (11%, pediatrics)</p>
<p><b>Frequency not reported</b>: Chills and fever, accidental injury<sup>[Ref]</sup></p><h3>Endocrine</h3><p>Opioids: </p>
<p><b>Postmarketing reports</b>: Adrenal insufficiency, androgen deficiency<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. OxyContin (oxycodone)." Purdue Frederick Company, Norwalk, CT. </p><p id="ref_2">2. Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992): 479-84</p><p id="ref_3">3. Glare P, Walsh D "Dose-ranging study of oxycodone for advanced cancer pain (meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 10 (1991): a1201</p><p id="ref_4">4. "Product Information. Xtampza ER (oxyCODONE)." Patheon, Durham, NC. </p><p id="ref_5">5. Sunshine A, Olson NZ, Zighelboim I, Decastro A "Ketoprofen, acetaminophen plus oxycodone, and acetaminophen in the relief of postoperative pain." Clin Pharmacol Ther 54 (1993): 546-55</p><p id="ref_6">6. Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992): 487-95</p><p id="ref_7">7. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_8">8. Glare PA, Walsh TD "Dose-ranging study of oxycodone for chronic pain in advanced cancer." J Clin Oncol 11 (1993): 973-8</p><p id="ref_9">9. Fishbain DA, Goldberg M, Rosomoff RS, Rosomoff H "Atypical withdrawal syndrome (organic delusional syndrome) secondary to oxycodone detoxification ." J Clin Psychopharmacol 8 (1988): 441-2</p><p id="ref_10">10. Fanoe S,  Jensen GB,  Sjogren P,  Korsgaard MP,  Grunnet M "Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro." Br J Clin Pharmacol 67 (2008): 172-9</p><p id="ref_11">11. Gardos G "Dyskinesia after discountinuation of compound analgesic containing oxycodone ." Lancet 1 (1977): 759-60</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Oxycodone vs Hydrocodone - How do they compare?</li>
<li>What is hydrochloride?</li>
<li>Oxycodone vs OxyContin - What's the difference?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Percolone (oxycodone)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>1 Review</li>
<li>Drug class: narcotic analgesics</li>
<li>FDA Alerts (2)</li>
</ul>
<h3>Consumer resources</h3>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>OxyContin, Roxicodone, Xtampza ER, Oxaydo, ... +8 more</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Chronic Pain</li>
<li>Pain</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to oxycodone: compounding powder, oral capsule, oral capsule extended release, oral concentrate, oral solution, oral tablet, oral tablet extended release</i></p><h3>General</h3><p>The most commonly reported adverse reactions in adults included constipation, nausea, somnolence, dizziness, vomiting, pruritus, headache, dry mouth, asthenia, and sweating.  In pediatric patients, the most frequently observed adverse reactions included vomiting, nausea, headache, pyrexia, and constipation.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (14%, pediatrics)</p><p><b>Common</b> (1% to 10%): Dizziness (pediatrics)</p><p><b>Frequency not reported</b>: Confusion, hypertonia, hypesthesia, nervousness, neuralgia, personality disorder, tremor, migraine</p><p><b>Postmarketing reports</b>: Serotonin syndrome<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Frequency not reported</b>: Apnea, respiratory arrest, bronchitis, cough increased, dyspnea, epistaxis, laryngismus, lung disorder, pharyngitis, rhinitis, sinusitis<sup>[Ref]</sup></p><p>Severe adverse effects such as respiratory depression can be treated with the opioid antagonist naloxone.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (23% to 27%), constipation (23% to 26%), vomiting (12% to 14%)</p><p><b>Frequency not reported</b>: Abdominal pain, anorexia, diarrhea, dyspepsia, dysphagia, gingivitis, glossitis<sup>[Ref]</sup></p><p>In pediatric studies with the oral extended release product, gastrointestinal adverse events were reported in 40% of patients 11 to 16 years of age (56 of 140); vomiting, nausea, constipation, and diarrhea were experienced by 21%, 15%, 9%, and 6%, respectively.  Abdominal pain and gastroesophageal reflux disease were reported in 1% to less than 5% of patients.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Paranoia, psychosis, hallucinations, agitation, anxiety<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Pruritus, hyperhidrosis, rash</p><p><b>Frequency not reported</b>: Herpes simplex, rash, sweating, urticaria<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Increased hepatic enzymes</p><h3>Cardiovascular</h3><p><b>Frequency not reported</b>: QTc prolongation at higher doses, deep thrombophlebitis, heart failure, hemorrhage, hypotension, palpitation, tachycardia, edema, peripheral edema, vasodilation, circulatory collapse<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Dysuria, urinary retention</p><p><b>Frequency not reported</b>: Urinary tract infection<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Allergic reaction</p><p><b>Postmarketing reports</b>: Anaphylaxis<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Flu syndrome, infection, sepsis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Decreased appetite (pediatrics)</p><p><b>Frequency not reported</b>: Gout, hyperglycemia, iron deficiency anemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Back pain, neck pain, arthralgia, arthritis, bone pain, myalgia, pathological fracture<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Photosensitivity reaction, amblyopia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (11%, pediatrics)</p><p><b>Frequency not reported</b>: Chills and fever, accidental injury<sup>[Ref]</sup></p><h3>Endocrine</h3><p>Opioids: </p><p><b>Postmarketing reports</b>: Adrenal insufficiency, androgen deficiency<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. OxyContin (oxycodone)." Purdue Frederick Company, Norwalk, CT. </p><p id="ref_2">2. Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992): 479-84</p><p id="ref_3">3. Glare P, Walsh D "Dose-ranging study of oxycodone for advanced cancer pain (meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 10 (1991): a1201</p><p id="ref_4">4. "Product Information. Xtampza ER (oxyCODONE)." Patheon, Durham, NC. </p><p id="ref_5">5. Sunshine A, Olson NZ, Zighelboim I, Decastro A "Ketoprofen, acetaminophen plus oxycodone, and acetaminophen in the relief of postoperative pain." Clin Pharmacol Ther 54 (1993): 546-55</p><p id="ref_6">6. Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992): 487-95</p><p id="ref_7">7. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_8">8. Glare PA, Walsh TD "Dose-ranging study of oxycodone for chronic pain in advanced cancer." J Clin Oncol 11 (1993): 973-8</p><p id="ref_9">9. Fishbain DA, Goldberg M, Rosomoff RS, Rosomoff H "Atypical withdrawal syndrome (organic delusional syndrome) secondary to oxycodone detoxification ." J Clin Psychopharmacol 8 (1988): 441-2</p><p id="ref_10">10. Fanoe S,  Jensen GB,  Sjogren P,  Korsgaard MP,  Grunnet M "Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro." Br J Clin Pharmacol 67 (2008): 172-9</p><p id="ref_11">11. Gardos G "Dyskinesia after discountinuation of compound analgesic containing oxycodone ." Lancet 1 (1977): 759-60</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Oxycodone vs Hydrocodone - How do they compare?</li>
<li>What is hydrochloride?</li>
<li>Oxycodone vs OxyContin - What's the difference?</li>
</ul><h2>More about Percolone (oxycodone)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>1 Review</li>
<li>Drug class: narcotic analgesics</li>
<li>FDA Alerts (2)</li>
</ul><h3>Consumer resources</h3><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Chronic Pain</li>
<li>Pain</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>